close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

470.87 -7.06 (-1.48%)
Streaming Delayed Price Updated: 10:15 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
70 71 Next >
News headline image
Vertex Grapples With Bearish Chart As Death Cross Emerges ↗
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months. 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip ↗
Via The Motley Fool
News headline image
Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals ↗
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK... 
Via Talk Markets
Topics Stocks / Equities
News headline image
3 No-Brainer Stocks to Buy on the Latest Sell-Off ↗
Via The Motley Fool
News headline image
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst ↗
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients. 
Via Benzinga
News headline image
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
Via Benzinga
Topics Economy
News headline image
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? ↗
Via The Motley Fool
News headline image
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2025 ↗
Via The Motley Fool
News headline image
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock ↗
The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock. 
Via Investor's Business Daily
News headline image
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
News headline image
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? ↗
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions. 
Via Benzinga
News headline image
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain ↗
The company says there was variability among placebo responses at various sites. 
Via Investor's Business Daily
News headline image
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. ↗
Vertex Pharmaceuticals' drug reduced back pain significantly. 
Via Investor's Business Daily
News headline image
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Unstoppable Stocks to Buy and Hold for the Next Decade ↗
Via The Motley Fool
News headline image
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗
Via The Motley Fool
News headline image
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗
Via The Motley Fool
News headline image
3 Unstoppable Stocks to Buy Right Now ↗
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today